DOCETAXEL

Docetaxel stabilizes microtubules and prevents mitotic spindle disassembly, used in breast, lung, and prostate cancers. Side effects include neutropenia, neuropathy, fluid retention, mucositis, and alopecia. Only GMP materials will be supplied, logistics all according to GDP.

Category:

Product Description


Mechanism of Action

DOCETAXEL displays a highdimensional biochemical interaction profile, integrating catalyticdomain modulation, multiaxis signalling interference, mitochondrialnetwork recalibration, ionflux redistribution, membranepotential rebalancing, cytoskeletal remodelling, redoxequilibrium restructuring and transcriptionfactor pathway reprogramming. Its molecular topology supports interaction with catalytic residues, allosteric microdomains, transmembrane helices, nucleotidebinding pockets, redoxbuffer centres and polymeric scaffolding complexes, enabling wideband influence across metabolic, genomic, structural and electrophysiological layers.

At the signalling level, DOCETAXEL may reconfigure phosphorylation landscapes spanning ERK/MAPK/JNK/p38 and PI3KAKT axes, modulate Gprotein coupling states, reorganise Ca²⁺ microdomain geometry, adjust IP/DAG cascade topology, and recalibrate cAMPPKA amplitude distributions. Mitochondrial effects can include ETCcomplex rebalancing, ATP/ADP flux modulation, ROSthreshold displacement, membranepotential polarity shifts and bidirectional stresssignal integration between ER and mitochondrial compartments.

Advanced

  • Kinomescale catalyticcascade interference mapping
  • Highresolution docking & conformationaltransition simulations
  • UPR/ERstress, mitophagy & autophagicflux network analysis
  • Full multiomics integration (RNAseq, proteomics, phosphoproteomics, metabolomics)
  • Cytoskeletal mechanics & polymerturnover/forcedistribution modelling
  • Cellfate pathway simulations (apoptosis, necroptosis, ferroptosis, parthanatos)
  • AIdriven SAR/QSAR pipelines for compoundperformance prediction

Toxicodynamics & Hazard Spectrum

  • Rapid ROS escalation & antioxidantbuffer saturation
  • Mitochondrial fragmentation or ETCaxis suppression
  • Severe Na⁺/K⁺/Ca²⁺ ionic-flux destabilisation
  • Cytoskeletal depolymerisation & membrane-integrity loss
  • Hyperactivation of NF-κB, STAT & IRF inflammatory regulators
  • Induction of multiaxis programmed-cell-death pathways
  • Epigenetic drift including methylation/acetylation imbalance

For expert laboratory research only not intended for biological or therapeutic exposure.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

C43H53NO14

Molecular Weight

807.9 g/mol

CAS Number

114977-28-5

Storage Condition

Store between 2 °C and 25 °C (36 °F and 77 °F). Retain in the original package to protect from light. Freezing does not adversely affect the product.

Solubility

Insoluble

Purity

Purity information is available upon request (COA).

Synonym

docetaxel; 114977-28-5; Taxotere; Docetaxel anhydrous; Docetaxel Kabi

IUPAC/Chemical Name

[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1,9,12-trihydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate

InChl Key

ZDZOTLJHXYCWBA-VCVYQWHSSA-N

InChl Code

InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1

References

https://pubchem.ncbi.nlm.nih.gov/compound/148124;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download